TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
TG THERAPEUTICS, INC. (TGTX) director Laurence N. Charney reported a sale of 5,000 shares of Common Stock on September 10, 2026. According to the filing, the Company’s restricted stock administrator sold these shares to satisfy Mr. Charney’s income tax obligations, at a volume-weighted average price of $54.96 per share.
After this tax-related sale, Mr. Charney held 168,640 shares directly, including restricted Common Stock that vests over various time periods. No transactions were reported under a Rule 10b5-1 trading plan.
TG THERAPEUTICS, INC. (TGTX) had a notice filed for a proposed sale of its common stock under Rule 144 by director Laurence N. Charney. The notice covers 5,000 shares of common stock, originally acquired from the issuer on January 1, 2023 through Restricted Stock Vesting as compensation.
The shares are held in an account at Fidelity Brokerage Services LLC and are proposed for sale on NASDAQ. The aggregate market value of the shares referenced in the notice is listed as $274,794.08. The form is signed by Daniel Tucci as a duly authorized representative of Fidelity, acting as attorney-in-fact for Laurence Charney.
TG Therapeutics director Laurence N. Charney reported three bona fide gifts of Common Stock totaling 6,050 shares on August 6–7, 2026. The shares were transferred at $0.00 per share to a 501(c)(3) institution, and he retains no beneficial ownership or pecuniary interest in the gifted stock. Remaining holdings are noted as including restricted Common Stock that vests over time.
TG Therapeutics, a commercial-stage biotech focused on B‑cell diseases, generated total revenue of $240.3 million for the quarter and $445.3 million for the first half of 2026, compared with $141.1 million and $262.0 million a year earlier, driven mainly by U.S. and ex‑U.S. sales of BRIUMVI for relapsing multiple sclerosis and related license and milestone revenue. Net income was $7.8 million for the quarter and $27.6 million year‑to‑date, with diluted EPS of $0.05 and $0.17, respectively.
Total assets reached about $1.64 billion, including $612.3 million in cash, cash equivalents and investment securities (excluding equity investments), while total liabilities were about $1.04 billion, reflecting a new $750 million term loan and repayment of a prior facility, which also produced a $9.2 million loss on extinguishment of debt. Management states it recently achieved profitability, expects existing liquidity and projected revenues to fund operations for more than twelve months, and does not currently expect to raise additional capital, though it may seek financing for strategic initiatives. The company highlights extensive risks around BRIUMVI’s market acceptance and regulation, dependence on partners and suppliers, high R&D and commercialization spending, significant stock‑based compensation, debt obligations and stock‑price volatility.
TG Therapeutics reported higher Q2 2026 revenue led by BRIUMVI. Total revenue reached $240.3 million, up from $141.1 million a year earlier. Product revenue was $235.8 million, driven by BRIUMVI U.S. net product revenue of $227.7 million, approximately 64% higher than the prior-year quarter, plus $8.1 million of BRIUMVI sales to ex-U.S. partner Neuraxpharm and $4.5 million of license, milestone, royalty and other revenue.
Operating income was $21.7 million, but net income declined to $7.8 million from $28.2 million as cost of revenue rose to $41.2 million, R&D expense increased to $95.3 million (including $54.6 million for subcutaneous BRIUMVI manufacturing and secondary manufacturer costs), and SG&A expense grew to $82.1 million, alongside higher interest expense of $16.6 million.
Cash, cash equivalents and investment securities were $612.3 million at June 30, 2026, and the company expects this plus projected BRIUMVI revenue to fund its current operating plan. Full‑year 2026 guidance was raised to approximately $950 million in total global revenue and $890–$905 million in BRIUMVI U.S. net product revenue, with targeted operating expenses of $350–$400 million excluding non‑cash compensation and about $100 million for subcutaneous BRIUMVI manufacturing and secondary manufacturer start‑up costs. Management also highlighted positive Phase 3 ENHANCE results and progress in subcutaneous BRIUMVI, myasthenia gravis, schizophrenia and the azer‑cel platform.
Lonial Sagar reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Sagar Lonial received a grant of 8,325 stock tracking units. Each unit is a contingent right to either one share of common stock or a cash payment equal to the fair market value of one share, generally within 30 days after the first anniversary of grant. The units vest on that first anniversary if he remains in continuous service, and this filing shows 8,325 units held after the grant.
HUME DANIEL reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Daniel Hume reported a compensation grant of 8,325 Stock Tracking Units (STUs). Each STU is a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The STUs vest on the first anniversary only if he remains in continuous service with the company, and he now holds 8,325 STUs directly.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Kenneth Hoberman received an equity-based award tied to the company’s stock. He was granted 8,325 Stock Tracking Units on June 11, 2026, each linked to one share of common stock.
Each unit represents a contingent right, at the board committee’s discretion, to deliver either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The units will vest on the first anniversary of the grant, provided he remains in continuous service with the company through that date.
Echelard Yann reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Yann Echelard received a grant of 8,325 stock tracking units as equity compensation. Each unit represents a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share. The committee administering the company’s 2022 Incentive Plan will choose stock or cash, and settlement must occur within 30 days after the first anniversary of the grant date. The units vest on the first anniversary of grant if Echelard remains in continuous service with the company.
TG Therapeutics director Laurence N. Charney received a grant of 8,325 Stock Tracking Units on June 11, 2026. These units were awarded as compensation and carry no exercise price.
Each Stock Tracking Unit represents a contingent right, at the discretion of the plan committee, to receive either one share of TG Therapeutics common stock or a cash payment equal to the fair market value of one share. This payment or share delivery is scheduled no later than 30 days after the first anniversary of the grant date, provided Charney remains in continuous service through that vesting date.
Following this award, Charney holds 8,325 Stock Tracking Units directly, each tied to an equivalent number of underlying common shares. The transaction does not involve any open-market buying or selling, and reflects a routine equity-based incentive grant.